Clinical Observation Of Guanxin Xiaoban Capsule On Anti-inflammatory And Antithrombotic Effects In Patients With Hyperlipidemia (phlegm And Blood Stasis)

Objective:To observe the improvement of blood lipid level,inflammatory factors,thrombosis risk and TCM syndromes in patients with dyslipidemia and phlegm-recovery syndrome with Guanxinxiaoban capsule.Methods: According to the inclusion criteria,TCM syndrome differentiation was all evidence of spasticity.64 patients with dyslipidemia were screened and randomly assigned to 32 cases in the experimental group and 32 cases in the control group.The experimental group was treated with Guanxinxiaoban capsule and the control group was treated with atorvastatin calcium tablets.The observation time was 6 weeks.Observe changes in blood lipids(TC,TG,HDL-C,LDL-C),inflammatory factors(hs-CRP,IL-6),thrombosis risk(DD,FIB,and Hcy)and TCM syndrome scores before and after treatment,and check Blood urine excrement,liver and kidney function,electrocardiogram,and whether any adverse reactions occurred during the observation period.Results:There was no statistically significant difference between the two groups in terms of gender,age,duration of disease,comorbidities,and laboratory indicators before and after treatment,as well as TCM symptom scores(P>0.05).At the end of the trial,two patients in the test group and the control group each withdrew.(1)Comparison of serum lipid levels: After treatment,serum TC,TG and LDL-C levels in both groups were significantly lower than those before treatment,and HDL-C levels were significantly higher than before treatment(P <0.05).There was no significant difference between the two groups in improving TC,TG,LDL-C and HDL-C in control group(P> 0.05).(2)The total clinical curative effect comparison: The total effective rate of two groups of patients after treatment were 93.33%,96.67%,the difference was not statistically significant(P> 0.05).(3)Comparison of TCM curative effect: The scores of TCM syndromes after treatment in both groups were lower than those before treatment,andthe difference was statistically significant(P<0.05).After TCM syndrome scores were compared between the two groups,the test group was lower than the control group.Statistically significant(P<0.05).The total clinical efficacy of Chinese medicine after treatment in the two groups was 96.67%and 73.33%,respectively,and the difference between the two groups was statistically significant(P<0.05).(4)Comparison of inflammatory factors:There was no significant difference in hs-CRP and IL-6 levels between the two groups before treatment(P> 0.05).After treatment,the hs-CRP and IL-6 in both groups were significantly decreased compared with those before treatment,(P<0.05).There was no significant difference between the control groups(P>0.05),and the difference between the two groups after treatment was statistically significant(P <0.05).(5)Comparison of thrombosis risk: The DD,FIB and Hcy in experimental group decreased significantly after treatment,the difference was statistically significant(P <0.05),while the control group DD was decreased after treatment,the difference was statistically significant(P<0.05),and the difference between FIB,Hcy and before treatment was not statistically significant(P> 0.05).The differences of DD,FIB and Hcy levels between the two groups after treatment were statistically significant(P <0.05).Conclusion:Guanxin Xiaoban capsule can effectively relieve the symptoms of traditional Chinese medicine,improve blood lipid levels,inhibit inflammatory factors,reduce the risk of thrombosis in patients with dyslipidemia and phlegm and blood stasis syndrome,and has fewer adverse reactions.